Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COLUMN
COLUMN
-
How Far Has Your Organization Come? Key Lessons Learned from Ongoing Commercial Transformations in Japan
September 11, 2023
-
Mission Impossible: Finding the Right Leader to Launch a Disruptive Medical Technology into Japan
August 10, 2023
-
How Healthcare Companies Should Hire in the Post-COVID Work Environment
July 19, 2023
-
The Impact of a Shrinking Labor Market on the Healthcare Industry
June 23, 2023
-
Seven Recruitment Trends in 2023
May 31, 2023
-
The Inflation Reduction Act - Implications for Japanese Pharmaceutical Manufacturers
May 19, 2023
-
How to Serve and Get Ahead
April 21, 2023
-
The Increasing Impact of Real-World Evidence
March 31, 2023
-
Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
-
Why Market Mapping Is Critical to Your Organization
February 24, 2023
-
When It Comes to Recruitment, Time Is Money. Have a Plan!
January 31, 2023
-
Cell Therapy in Japan: A Potentially Attractive Market at a Turning Point Facing Challenges
December 16, 2022
-
How to Succeed in Bad Times and Good
December 9, 2022
-
The Pros and Cons of Working from Home in 2022
November 25, 2022
-
Rare Diseases in Japan: Moving from Treatment to Integrated Care
October 27, 2022
-
The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
-
Fairness, Not Diversity
August 26, 2022
-
Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
August 5, 2022
-
The Winning Combination: Drive, Passion, and Commitment
July 22, 2022
-
Please Come Back to the Office!
June 24, 2022
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…